MYB/c-Myb Drug Discovery Landscape & Assay Solutions

  • By admin
  • 04 Aug 2026
  • Comments

Market Intelligence, Clinical Progress, and High-Purity Reagents for Leukemia and Adenoid Cystic Carcinoma (ACC) Development.

TarMart Solution Ecosystem & Related Targets

Comprehensive reagent toolkit for MYB drug discovery. Select your modality below:

Component / Network Product Description Product Link
Antigen MYB Recombinant Protein (Full-Length, DBD R1R2R3, WT & Mutant Panels)
High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Suitable for PROTAC binding, PPI, and DNA binding assays.		 View MYB Products
Gene Delivery MYB Promise-ORF / Lentivirus
Full-length ORF for stable reporter cell lines and overexpression studies. Essential for intracellular degradation assays.		 View MYB Products
Benchmark Ab Anti-MYB Benchmark Control (ChIP-Grade)
Recombinant positive control for western blot, IP, and ChIP.		 View MYB Products
Validator MYB siRNA Set
For knockdown verification and genetic specificity controls.		 View MYB Products
Related Target A EP300 (p300)
Critical co-activator; targeted for PPI disruption.		 View EP300 Products
Related Target B NFIB
Fusion partner in Adenoid Cystic Carcinoma (MYB-NFIB).		 View NFIB Products
Related Target C CDK9
Transcriptional addiction target; synergistic with MYB inhibition in AML.		 View CDK9 Products
Related Target D CEBPA (C/EBPα)
Direct protein interaction partner; heterodimeric transcriptional regulation.		 View CEBPA Products
Related Target E MYBL2 (B-Myb)
Subfamily paralog for selectivity and off-target counter-screening.		 View MYBL2 Products
Related Target F MEN1 (Menin)
Critical PPI partner in MYB-driven leukemia; co-target validation.		 View MEN1 Products
Critical Assay Challenge The TarMart Advantage (Technical Spec)
PROTAC / Small Molecule Binding Validation Sequence Verified, High Purity (>95%) Recombinant Proteins suitable for SPR/BLI.
Assaying Intracellular Target Degradation Lentivirus Premade Particles for rapid stable cell line construction (Flow/WB assays).
Lack of Controls for PPI Assays Clinical Benchmark Antibodies included for precise assay calibration.
False Positives in Screening Validated siRNA included for specificity and orthogonal checks.
Protein-Protein Interaction Screening (MYB-C/EBP, MYB-p300) High-purity DBD (R1R2R3) constructs with verified folding; Human/Mouse orthologs available.
DNA Binding Competition Assays (EMSA/FP) Sequence-verified DNA-binding domain with confirmed consensus sequence binding; Endotoxin <0.1 EU/μg.
Mutant Validation (Oncogenic Variants) Leukemia-associated mutants available (e.g., truncations); Theoretical MW verified by Mass Spec.
Subfamily Off-Target Liability (MYBL1/MYBL2) Paralog panel (MYBL2) with mass-spec verified theoretical MW for selectivity screening.
Non-Specific Signal in Cell-Based Reporter Assays Sequence-verified siRNA set for target-specificity validation.

MYB Functional Domains & Key Mutations

MYB (c-Myb) contains three conserved HTH (helix-turn-helix) myb-type DNA-binding domains (dbSNP evidence: UniProt P10242):

  • HTH myb-type 1 (residues 38–86)
  • HTH myb-type 2 (residues 89–137)
  • HTH myb-type 3 (residues 142–190)

Key missense mutations reported in human populations (UniProt P10242):

  • rs2229999 (p.Thr194Met)
  • rs2230000 (p.Ser233Leu)

These domains and variants are critical for DNA-binding affinity and transcriptional activity in AML and ACC. TarMart provides recombinant proteins covering these domains and mutation panels for mechanistic studies.

Live MYB/c-Myb R&D Tracker

Market data changes daily. Access the latest global pipeline status directly:

Global Clinical Landscape & Future Outlook

The race for MYB-directed therapeutics is intensifying, with major players shifting focus from traditional modalities to targeted protein degraders (PROTACs/molecular glues) and protein-protein interaction (PPI) inhibitors. As a master transcription factor driving oncogenesis in acute myeloid leukemia (AML) and adenoid cystic carcinoma (ACC), MYB has long been considered “undruggable.” While indirect strategies (CDK9, BET, Menin inhibitors) show limitations in specificity, the next wave of R&D is heavily targeting direct MYB modulation through peptide mimetics, allosteric inhibitors, and PPI disruptors (e.g., MYB-p300/CBP, MYB-C/EBPα). Recent advances in structural biology and AI-driven drug design are enabling rational targeting of transcription factor surfaces.

Competitive Modality & Indication Snapshot

Modality Representative Players Key Indications Critical Assay Need (Why TarMart?)
PROTAC / Degrader Biotech Innovators, Academic Hubs AML, ALL, MDS Ternary Complex Validation (Need High-Purity Recombinant Proteins and Lentivirus stable lines)
PPI Inhibitors (Small Mol / Peptide) Emerging Pharma, Academic Consortia Adenoid Cystic Carcinoma, AML Interaction Assays (Need pure MYB, EP300/CBP, C/EBPα components)
Indirect (CDK9, BET, Menin Inhibitors) AstraZeneca, Pfizer, Preclinical Biotech Hematologic Malignancies Combination studies require MYB reporter cell lines (Lentivirus-based) to measure transcriptional output
Gene Therapy / Vaccines Specialized Biotech Solid Tumors, Leukemias Expression Tracking (Need Reliable Benchmark Antibodies and siRNA tools)
Peptide / Stapled Peptide Preclinical Academic Groups Solid Tumors (Breast, Colon) Cell penetration validation using lentiviral MYB fusion reporters

TarMart Product Highlights

  • Recombinant Proteins: Full-length, DBD (R1R2R3), and mutant panels >95% purity, endotoxin <1 EU/µg, sequence verified.
  • Lentivirus Premade Particles: Full-length ORF for rapid stable cell line construction, essential for degradation and reporter assays.
  • Benchmark Antibodies: ChIP-grade reference clones for target engagement and detection.
  • siRNA Validator Sets: For knockdown specificity and orthogonal validation.
  • Cross-Species Orthologs: Human, mouse, cyno MYB available for translational studies.

References

  • UniProt P10242 (MYB primary entry)
  • ClinicalTrials.gov, PubMed, Google Patents (live links above)